Homeopathic treatment of enlarged prostate

Effectiveness of individualized homoeopathic medicines and mother tinctures in benign prostatic hypertrophy: an open randomized pragmatic trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/013584

Enrollment

120

Registered

2018-05-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Benign Prostatic Hypertrophy (BPH)

Interventions

Intervention1: Indicated homeopathic medicines in centesimal or fifty millesimal potencies: Indicated homeopathic medicines in centesimal or fifty millesimal potencies, as decided appropriate to the c

dosage and repetition depending upon the individual requirement of the cases. In 50 millesimal scale, a single medicated cane sugar globules of poppy seed size (no. 10) shall be dissolved in 90 ml dis

16 doses to be marked on the vial

each dose of 5 ml to be taken after 10 uniformly forceful downward strokes to the vial in 45 ml normal water in a clean cup, to stir well, to take 5 ml of this liquid orally, and to discard rest of th

be taken orally on clean tongue with empty stomach. Duration of therapy: 6 months Control Intervention2: Individualized homeopathic medicines plus Hydrangea arborescens or Sabal serrulata mother tinct

dosage and repetition depending upon the individual requirement of the cases. In 50 millesimal s

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 30-80 years 2. Presenting symptoms of prostatism, with or without evidence of bladder outflow obstruction [AUASS > 7] 3. Ultrasonographic examination prostate weight > 20 g/20 cc and RUV of > 30 ml 4. Patients already undergoing regular therapy for BHP, provided the medications are stopped completely at least 2 weeks prior study entry 5. Ability to read English or Bengali 6. Providing written informed consent to participate

Exclusion criteria

Exclusion criteria: 1. Patients not adequately symptomatic [AUASS 2. Patients with serum prostate specific antigen (PSA) > 4 nmol/mL to rule out suspected prostatic malignancy 3. Complete urinary retention/stone formation 4. Gross bilateral hydronephrosis 5. Other possible causes of urinary retention, such as recurrent urinary tract infection, neurogenic bladder or urethral stricture 6. Patients insisting for surgery during the next 6 months 7. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any vital organ failure 8. Substance abuse and/or dependence 9. Self-reported immune-compromised state 10. Undergoing homeopathic treatment for any chronic disease within last 6 months 11. Patients who are too sick for consultation and not willing to cooperate 12. Unable to read patient information sheet 13. Unwilling to take part and not giving consent to join the study

Design outcomes

Primary

Measure	Time frame
Translated Bengali version of American Urology Association Symptom Score (AUASS)Timepoint: At baseline, after 3 months and 6 months	—

Secondary

Measure	Time frame
Prostate size and RUVTimepoint: At baseline and after 6 months	—

Countries

India

Contacts

Public ContactChintamani Nayak

National Institute of Homoeopathy, Ministry of AYUSH, Govt. of India

drcnayak@gmail.com9433161854

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026